Qiagen N : Investor Presentation January 9, 2023

A balanced business driven by focus and execution

Commerzbank and ODDO BHF German Investment Seminar, New York

Roland Sackers

Chief Financial Officer

Disclaimer

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including factors such as general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to "Risk Factors" section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

January 9, 2023

Commerzbank and ODDO BHF German Investment Seminar

2

Our Mission	Our Vision
Enabling access to valuable	Making improvements
insights from molecular	in life possible
research to clinical healthcare

January 9, 2023

Commerzbank and ODDO BHF German Investment Seminar

3

Balance: Well-diversified business spanning attractive markets

Diversified

customer base

Well-balanced leadership in

Life Sciences and

Molecular Diagnostics

Broad

geographic reach

>6,300 QIAGENers ensuring

access to attractive markets with

shipments to >170 countries

Highly

recurring revenues

Growing installed base generating demand for high-margin consumables

Life		Molecular
Sciences		Diagnostics
		$2.2
	$1.9
$1.5		50%
	52%
52%
48%		50%
48%
2019	2020	2021

Net sales (In $ billions at actual rates)

~20%

Asia Pacific	~45%
/ Japan	Americas

~35%

EMEA

~88%

Consumables and related revenues

~12%

Instruments

January 9, 2023

Commerzbank and ODDO BHF German Investment Seminar

4

Focus: Leveraging a strong core portfolio to drive 5 Pillars of Growth

5 Pillars of Growth

Expanding on solid leadership	Early commercialization phases with strong growth potential
Sample	QuantiFERON	QIAstat-Dx	NeuMoDx	QIAcuity
technologies	Leading immune	Syndromic testing with	Differentiated microfluidic	Novel microplate digital
Comprehensive portfolio	response monitoring	unrivaled ease of use	integrated PCR testing	PCR
	(incl. TB)

	Sample technologies	Diagnostic solutions	PCR / Nucleic acid	NGS / Genomics
	amplification
2021	$851 m	$639 m	$434 m	$245 m
sales

Core

portfolios

Microbiome

Liquid

HID /

Immune

Infectious

Oncology /

OEM Reagents

Universal

QIAGEN

Biopsy

Forensics

response

diseases

Precision

NGS solutions

Digital Insights

Medicine

January 9, 2023

Commerzbank and ODDO BHF German Investment Seminar

5